Zydus receives approvals for Lansoprazole and Linagliptin Tablets

Zydus Cadila, a global pharmaceutical company, informed in a press release that the company has received USFDA approvals for Lansoprazole Tablets and Linagliptin Tablets. 
  
Zydus Cadila has received the final approval from the USFDA to market Lansoprazole delayed-release orally disintegrating tablets (US RLD- Prevacid), 15 mg and 30 mg and tentative approval for Linagliptin tablets (US RLD- Tradjenta), 5 mg. 
  
Lansoprazole is in a class of drugs called proton pump inhibitors (PPI) which blocks the production of acid by the stomach. Proton pump inhibitors are used for the treatment of conditions such as ulcers, gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome that are caused by stomach acid. Lansoprazole, like other proton-pump inhibitors, blocks the enzyme in the wall of the stomach that produces acid. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. 
  
Linagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. 
  

At 14:32 pm, the stock traded at per share price of Rs. 356.70 on NSE. The benchmark index BSE Sensex showed gains of 508.78 points to trade at 36,225.73.